The neuromuscular division at the University of Pittsburgh Department of Neurology provides care for neuromuscular patients including those seen in the affiliated Muscular Dystrophy Association Care Center and ALSA Center of Excellence (UPMC Presbyterian campus).
David Lacomis, MD, division chief, is director of the MDA Care Center and Co-Director of the EMG Laboratory. As the Director of Clinical Research for the Center for ALS Research, he oversees ALS research within the department and UPMC and in collaboration with basic science colleagues. He is also in charge of the muscle and nerve pathology service in the Division of Neuropathology and performs EMG-and ultrasound-directed needle muscle biopsies.
Tawfiq Al-Lahham, MD, is the Director of the ALS program including the ALSA Certified Center of Excellence and all clinical research projects. In addition to treating patients with amyotrophic lateral sclerosis and other neuromuscular diseases such as TTR amyloidosis, he is the site principal investigator in the Healey Platform drug trials in ALS. Dr. Al-Lahham also performs electrodiagnostic testing at the UPMC Presbyterian and Shadyside campuses and directs the newly approved Neuromuscular Medicine fellowship.
Paula R. Clemens, MD, actively conducts a research program with an emphasis on human clinical research for drug development and clinical trial readiness for muscular dystrophies. Dr. Clemens has previously been the Study Chair for two major clinical trials: a multi-site program testing a first-in-class steroid for treatment of patients with Duchenne and Becker muscular dystrophies, and for an exon 53 skipping drug clinical trial that provided the pivotal data resulting in drug approval by FDA and PMDA using the accelerated approval pathway. Additionally, she’s involved in human clinical research testing enzyme replacement therapy, chaperone small molecule therapy and adeno-associated viral vector-delivered gene replacement therapy for patients with late onset Pompe disease. Dr. Clemens directs the University of Pittsburgh NeuroNEXT clinical study site (funded by NINDS) and pursues pre-clinical, translational research in collaboration with Dr. Dana Ascherman (Rheumatology), studying an animal model of inflammatory myopathy.
Fang Sun, MD, PhD, specializes in myasthenia gravis and genetic as well as other autoimmune neuromuscular diseases. She sees patients and performs electrodiagnostic testing at the UPMC Presbyterian and Shadyside campuses, and she does clinical research in myasthenia gravis, including CAR-T cell therapy.
Joshua Smith, DO, treats patients with all types of neuromuscular disorders and performs electrodiagnostic testing, neuromuscular ultrasound, and needle muscle biopsies at UPMC Presbyterian and in the Wexford office. He is the director of the Autonomics Laboratory at the UPMC Presbyterian, runs a specialty clinic for Charcot-Marie-Tooth disease and is in charge of the EMG component of the clinical neurophysiology fellowship.
Jonathan Brent, MD, PhD, sees patients with all types of neuromuscular disorders, including ALS, and performs electrodiagnostic testing on the UPMC Presbyterian campus. His laboratory’s focus is on mutations in KIF5A, a type of motor protein, that may have a role in causing ALS and other motor neuron disorders. Dr. Brent studies how motor proteins function in neurons, and how and why mutations in these proteins may cause ALS. He is also interested in other genetic variants that may cause or contribute to neuromuscular diseases, especially ALS.
Rebecca Molczan, MSN, CRNP is a neuromuscular nurse practitioner who serves as the coordinator of the MDA Care Center and facilitates patient care and activities in the neuromuscular division.
